Breast cancer, Secondary cancers
Results
Phase 3
This trial compared datopotamab deruxtecan and standard chemotherapy for breast cancer.
It was for people with breast cancer that:
couldn’t be removed with surgery or had spread to another part of the body
had large amounts of hormone receptors (hormone receptor positive or HR positive cancer)
had a small number of receptors for the protein HER2 (HER2 negative cancer)
The trial was open for people to join between 2021 and 2022. The team published the results in 2024.
Recruitment start: 18 October 2021
Recruitment end: 26 December 2022
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Schmid
AstraZeneca
Last reviewed: 10 Mar 2025
CRUK internal database number: 17902
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
